Literature DB >> 30429688

Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus.

Samie Sabet, Michelle E Condren, Angela F Boston, Lauren C Doak, Laura J Chalmers.   

Abstract

Despite pharmacotherapeutic advancements in the management of type 1 diabetes mellitus during the past several decades, patients struggle to achieve glycemic goals. Additionally, hypoglycemia, especially in extremes of age, decreases quality of life. The lack of optimal glycemic control and risk for hypoglycemia are multifactorial. Nevertheless, endeavors aiming to develop pharmacotherapeutic options with enhanced pharmacokinetic, pharmacodynamic, and clinical profiles continue. This review article discusses recent ventures in 3 categories of insulin, non-insulin, and glucagon products.

Entities:  

Keywords:  diabetes; glucagon; insulin; non-insulin; pediatrics; type 1 diabetes mellitus

Year:  2018        PMID： 30429688      PMCID： PMC6213629          DOI： 10.5863/1551-6776-23.5.351

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN： 1551-6776


  53 in total

1.  Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group.

Authors:  Reinhard W Holl; Peter G F Swift; Henrik B Mortensen; Helle Lynggaard; Phillip Hougaard; Henk-Jan Aanstoot; Francesco Chiarelli; Denis Daneman; Thomas Danne; Harry Dorchy; Patrick Garandeau; Steven Greene; Hilary M C V Hoey; Eero A Kaprio; Mirjana Kocova; Pedro Martul; Nobuo Matsuura; Kenneth J Robertson; Eugen J Schoenle; Oddmund Sovik; Rosa-Maria Tsou; Maurizio Vanelli; Jan Aman
Journal:  Eur J Pediatr       Date:  2002-11-26       Impact factor: 3.183

2.  Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.

Authors:  Maryam Fath; Thomas Danne; Torben Biester; Lars Erichsen; Olga Kordonouri; Hanne Haahr
Journal:  Pediatr Diabetes       Date:  2017-02-06       Impact factor: 4.866

3.  Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.

Authors:  Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

4.  Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.

Authors:  Bo Ahrén; Irl B Hirsch; Thomas R Pieber; Chantal Mathieu; Fernando Gómez-Peralta; Troels Krarup Hansen; Areti Philotheou; Sune Birch; Erik Christiansen; Thomas Jon Jensen; John B Buse
Journal:  Diabetes Care       Date:  2016-08-04       Impact factor: 19.112

5.  Stability of Commercially Available Glucagon Formulation for Dual-Hormone Artificial Pancreas Clinical Use.

Authors:  Nadine Taleb; Adèle Coriati; Christian Khazzaka; Jonathan Bayonne; Virginie Messier; Rémi Rabasa-Lhoret
Journal:  Diabetes Technol Ther       Date:  2017-08-28       Impact factor: 6.118

6.  The hospital and home use of a 30-second hand-held blood ketone meter: guidelines for clinical practice.

Authors:  T M Wallace; N M Meston; S G Gardner; D R Matthews
Journal:  Diabet Med       Date:  2001-08       Impact factor: 4.359

Review 7.  Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes.

Authors:  Fida Bacha; Sara Klinepeter Bartz
Journal:  Pediatr Diabetes       Date:  2015-11-23       Impact factor: 4.866

8.  Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study.

Authors:  Kristen J Nadeau; Kelsey Chow; Suhyla Alam; Kara Lindquist; Sarah Campbell; Kim McFann; Georgeanna Klingensmith; Phillipe Walravens
Journal:  Pediatr Diabetes       Date:  2014-04-03       Impact factor: 4.866

Review 9.  Type 1 diabetes, metabolic syndrome and cardiovascular risk.

Authors:  Juan J Chillarón; Juana A Flores Le-Roux; David Benaiges; Juan Pedro-Botet
Journal:  Metabolism       Date:  2013-10-24       Impact factor: 8.694

10.  Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

Authors:  Urd Kielgast; Thure Krarup; Jens Juul Holst; Sten Madsbad
Journal:  Diabetes Care       Date:  2011-05-18       Impact factor: 19.112
View more
  1 in total

Review 1.  Diabetic‑induced alterations in hepatic glucose and lipid metabolism: The role of type 1 and type 2 diabetes mellitus (Review).

Authors:  Saizhi Jiang; Jamie L Young; Kai Wang; Yan Qian; Lu Cai
Journal:  Mol Med Rep       Date:  2020-05-22       Impact factor: 2.952
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.